# GeparSixto

Source: https://onco.cc/trials/geparsixto/  
OnCo record `geparsixto` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GeparSixto showed that adding carboplatin to chemotherapy given before surgery made triple-negative breast tumours disappear completely far more often, and in longer follow-up cut relapses, which put platinum into the standard neoadjuvant regimen for this type.

## Summary

GeparSixto randomised 595 women with early triple-negative or HER2-positive breast cancer to 18 weeks of weekly paclitaxel and non-pegylated liposomal doxorubicin, with bevacizumab for triple-negative and trastuzumab plus lapatinib for HER2-positive disease, with or without weekly carboplatin. The primary endpoint was pathological complete response.

Carboplatin increased the pathological complete response rate in triple-negative disease, and in longer follow-up improved disease-free survival in that group, but did not help HER2-positive disease and added haematological toxicity. Together with CALGB 40603 and later BrighTNess it established carboplatin as part of neoadjuvant chemotherapy for triple-negative breast cancer, the backbone that KEYNOTE-522 then added pembrolizumab to.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Also known as: GBG 66
- Tags: subtype-trials
- Registry id: NCT01426880
- Phase: 2/3
- Setting: Early triple-negative and HER2-positive breast cancer: neoadjuvant paclitaxel and non-pegylated liposomal doxorubicin (with bevacizumab in triple-negative and trastuzumab plus lapatinib in HER2-positive disease) with or without carboplatin
- Sponsor: German Breast Group (GBG Forschungs GmbH)
- Enrolled: 595
- Result: Carboplatin increased pathological complete response and improved disease-free survival in triple-negative breast cancer, without benefit in HER2-positive disease.

## Sources

- ClinicalTrials.gov NCT01426880: https://clinicaltrials.gov/study/NCT01426880

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Lapatinib](https://onco.cc/drugs/lapatinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- people: [Gunter von Minckwitz](https://onco.cc/people/gunter-von-minckwitz/)

---
JSON: https://onco.cc/api/v1/entities/geparsixto.json